Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01093573

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

RATIONALE: Midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Midostaurin may help azacitidine kill more cancer cells by making the cancer cells more sensitive to the dru

Status: 
Recruiting
Study Date: 
Wed, 07/01/2009 to Fri, 07/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: midostaurin Given orally Other Names: N-benzoyl-staurosporine PKC412 Drug: azacitidine Given IV Other Names: 5-AC 5-azacytidine 5-AZC azacytidine ladakamycin Vidaza Other: laboratory biomarker analysis Correlative study Other: bone marrow aspiration Correlative study Other: liquid chromatography Correlative study Other Name: LC Other: flow cytometry Correlative study Other: mutation analysis Correlative study Other: pharmacological study Correlative study Other Name: pharmacological studies Other: mass spectrometry Correlative study Other: protein expression analysis Correlative study